Use of Platelet Rich Plasma Gel on Wound Healing: A Systematic Review and Meta-AnalysisePlasty: Vol. 11
Data Reveals Less Invasive FUE Hair Transplant Trend is Accelerating

Kythera Biopharmaceuticals Announces $37.4M Financing for ATX-101 Synthetic Fat Melting Injection

Return to Current Article

Kythera Newsroom

LOS ANGELES, Sept. 19 (Business Wire) – KYTHERA Biopharmaceuticals, Inc. (“KYTHERA”), a privately-held biotechnology company focused on the development and commercialization of products in aesthetic medicine, today announced the closing of a $37.4M Series D financing. The round featured significant new investments as well as participation from all existing institutional investors. Proceeds from this financing are slated to be used for conducting US Phase III trials for KYTHERA’s lead product, ATX-101, a first-in-class, injectable drug that is under investigation for the reduction of submental (‘under the chin’) fat.

It would appear that ATX-101 holds some promise for those looking for an injection that reduces submental (chin/neck) fat. --Dr. Alan Bauman

comments powered by Disqus